Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388656 · ClinicalTrials.gov registry record · Phase 4
Estrogen Variability and Irritability During the Menopause Transition
A Phase 4 study of Menopause and Irritable Mood, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05388656 is a Phase 4 study of Menopause and Irritable Mood that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05388656, a Phase 4 study of Menopause and Irritable Mood, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. The purpose of this research is to determine the neurophysiologic basis of susceptibility to estradiol fluctuations and irritability symptoms in perimenopausal women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release
- DRUG Progesterone 200 mg
Study Locations (1)
North Carolina
- Carolina Crossing B, Suite 1 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388656
The ClinicalTrials.gov registry entry for NCT05388656 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05388656 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05388656 about?
NCT05388656 is a clinical study titled "Estrogen Variability and Irritability During the Menopause Transition". Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimen...
What is the current status of trial NCT05388656?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2022-06-15. Estimated completion is 2025-01-17.
What conditions does trial NCT05388656 study?
This clinical trial studies the following conditions: Menopause, Irritable Mood.
What interventions are being tested in trial NCT05388656?
The interventions under investigation include: Placebo (DRUG), Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release (DRUG), Progesterone 200 mg (DRUG).
Who is sponsoring clinical trial NCT05388656?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05388656 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiometabolic Consequences of the Loss of Ovarian Function
RECRUITING · Phase 4
-
Role of Menopause in Thermoregulation
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Nuvigil on Fatigue
COMPLETED · Phase 4
-
Hormone Estradiol Replacement Therapy Additional Herbals
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.